卵胞质内单精子注射(ICSI)技术中国专家共识(2023年)  

Chinese expert consensus on intracytoplasmic sperm injection(2023)

作　　者：中国医师协会生殖医学专业委员会 李蓉[2] 李达[3] 章志国[4] 杨大磊[5] Chinese Association of Reproductive Medicine;Li Rong;Li Da;Zhang Zhiguo(不详;Center for Reproductive Medicine,Department of Obstetrics and Gynecology,Peking University Third Hospital,Beijing 100191,China;Center for Reproductive Medicine,Shengjing Hospital of China Medical University,Shenyang 110022,China;Reproductive Medicine Center,Department of Obstetrics and Gynecology,the First Affiliated Hospital of Anhui Medical University,Hefei 230022,China)

机构地区：[1]不详 [2]北京大学第三医院妇产科生殖医学中心,北京100191 [3]中国医科大学附属盛京医院生殖医学中心,沈阳110022 [4]安徽医科大学第一附属医院妇产科生殖中心,合肥230022 [5]中国医科大学附属盛京医院

出　　处：《中华生殖与避孕杂志》2023年第7期659-669,共11页Chinese Journal of Reproduction and Contraception

摘　　要：人类卵胞质内单精子注射(intracytoplasmic sperm injection,ICSI)技术开展至今已有30余年。其最初主要应用于针对严重少、弱、畸形精子症导致的男性不育患者的治疗,但随着未成熟卵体外培养、卵子冷冻、胚胎植入前遗传学检测等辅助生殖技术的开展,ICSI使用比例已大幅提升。虽然目前ICSI技术相对成熟,但仍有很多细节值得关注和完善。为规范与优化人类辅助生殖技术从业者的ICSI操作,由中国医师协会生殖医学专业委员会发起,并联合全国多家生殖医学中心共同编撰了本共识。Intracytoplasmic sperm injection(ICSI)has been developed for over 30 years.Initially,it was mainly used in the treatment of male infertility caused by severe oligozoospermia,asthenozoospermia and teratozoospermia.However,the use of ICSI has substantially increased due to the extensive development of assisted reproductive technology such as in vitro maturation of immature oocytes,oocyte cryopreservation and preimplantation genetic testing.Although ICSI technology is relatively mature,there are still many details that need to be improved.In order to standardize and optimize the technology of ICSI,this consensus is initiated by the Chinese Association of Reproductive Medicine,and coedited with other reproductive medicine centers.

关 键 词：生殖技术 辅助 精子注射 细胞质内 共识 

分 类 号：R714.8[医药卫生—妇产科学]